GEMINI THERAPEUTICS
Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, they are developing a series of potentially first-in-class therapeutics.
GEMINI THERAPEUTICS
Industry:
Biopharma Biotechnology Health Diagnostics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.geminitherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
139.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Valkyrie GRP
Valkyrie GRP is a growth-oriented investment firm that focuses on team development, early distribution, and solid, value-added partnerships.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Atlas Venture
Atlas Venture investment in Post-IPO Equity - Gemini Therapeutics
Foresite Capital
Foresite Capital investment in Post-IPO Equity - Gemini Therapeutics
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Gemini Therapeutics
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Gemini Therapeutics
Lightstone Ventures
Lightstone Ventures investment in Post-IPO Equity - Gemini Therapeutics
Acorn Bioventures
Acorn Bioventures investment in Post-IPO Equity - Gemini Therapeutics
Alyeska Investment Group
Alyeska Investment Group investment in Post-IPO Equity - Gemini Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Post-IPO Equity - Gemini Therapeutics
Wellington Management
Wellington Management investment in Post-IPO Equity - Gemini Therapeutics
Boxer Capital
Boxer Capital investment in Post-IPO Equity - Gemini Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-05-07 | Gemini Therapeutics Names Ex-Achillion Exec Marc Uknis Chief Medical Officer |
Official Site Inspections
http://www.geminitherapeutics.com Semrush global rank: 4.15 M Semrush visits lastest month: 2.88 K
Unable to get host informations!!!
